TY - JOUR
T1 - Increasing test specificity without impairing sensitivity: lessons learned from SARS-CoV-2 serology
AU - Perkmann, Thomas
AU - Koller, Thomas
AU - Perkmann-Nagele, Nicole
AU - Ozsvar-Kozma, Maria
AU - Eyre, David
AU - Matthews, Philippa
AU - Bown, Abbie
AU - Stoesser, Nicole
AU - Breyer, Marie-Kathrin
AU - Breyer-Kohansal, Robab
AU - Burghuber, Otto C
AU - Hartl, Slyvia
AU - Aletaha, Daniel
AU - Sieghart, Daniela
AU - Quehenberger, Peter
AU - Marculescu, Rodrig
AU - Mucher, Patrick
AU - Radakovics, Astrid
AU - Klausberger, Miriam
AU - Duerkop, Mark
AU - Holzer, Barbara
AU - Hartmann, Boris
AU - Strassl, Robert
AU - Leitner, Gerda
AU - Grebien, Florian
AU - Gerner, Wilhelm
AU - Grabherr, Reingard
AU - Wagner, Oswald F
AU - Binder, Christoph J
AU - Haslacher, Helmuth
N1 - Publisher Copyright:
© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.
PY - 2023/11/1
Y1 - 2023/11/1
N2 - Background Serological tests are widely used in various medical disciplines for diagnostic and monitoring purposes. Unfortunately, the sensitivity and specificity of test systems are often poor, leaving room for false-positive and false-negative results. However, conventional methods were used to increase specificity and decrease sensitivity and vice versa. Using SARS-CoV-2 serology as an example, we propose here a novel testing strategy: the 'sensitivity improved two-test' or 'SIT²' algorithm. Methods SIT² involves confirmatory retesting of samples with results falling in a predefined retesting zone of an initial screening test, with adjusted cut-offs to increase sensitivity. We verified and compared the performance of SIT² to single tests and orthogonal testing (OTA) in an Austrian cohort (1117 negative, 64 post-COVID-positive samples) and validated the algorithm in an independent British cohort (976 negatives and 536 positives). Results The specificity of SIT² was superior to single tests and non-inferior to OTA. The sensitivity was maintained or even improved using SIT² when compared with single tests or OTA. SIT² allowed correct identification of infected individuals even when a live virus neutralisation assay could not detect antibodies. Compared with single testing or OTA, SIT² significantly reduced total test errors to 0.46% (0.24-0.65) or 1.60% (0.94-2.38) at both 5% or 20% seroprevalence. Conclusion For SARS-CoV-2 serology, SIT² proved to be the best diagnostic choice at both 5% and 20% seroprevalence in all tested scenarios. It is an easy to apply algorithm and can potentially be helpful for the serology of other infectious diseases.
AB - Background Serological tests are widely used in various medical disciplines for diagnostic and monitoring purposes. Unfortunately, the sensitivity and specificity of test systems are often poor, leaving room for false-positive and false-negative results. However, conventional methods were used to increase specificity and decrease sensitivity and vice versa. Using SARS-CoV-2 serology as an example, we propose here a novel testing strategy: the 'sensitivity improved two-test' or 'SIT²' algorithm. Methods SIT² involves confirmatory retesting of samples with results falling in a predefined retesting zone of an initial screening test, with adjusted cut-offs to increase sensitivity. We verified and compared the performance of SIT² to single tests and orthogonal testing (OTA) in an Austrian cohort (1117 negative, 64 post-COVID-positive samples) and validated the algorithm in an independent British cohort (976 negatives and 536 positives). Results The specificity of SIT² was superior to single tests and non-inferior to OTA. The sensitivity was maintained or even improved using SIT² when compared with single tests or OTA. SIT² allowed correct identification of infected individuals even when a live virus neutralisation assay could not detect antibodies. Compared with single testing or OTA, SIT² significantly reduced total test errors to 0.46% (0.24-0.65) or 1.60% (0.94-2.38) at both 5% or 20% seroprevalence. Conclusion For SARS-CoV-2 serology, SIT² proved to be the best diagnostic choice at both 5% and 20% seroprevalence in all tested scenarios. It is an easy to apply algorithm and can potentially be helpful for the serology of other infectious diseases.
KW - allergy and immunology
KW - medical laboratory science
KW - serology
UR - http://www.scopus.com/inward/record.url?scp=85137691679&partnerID=8YFLogxK
U2 - 10.1136/jcp-2022-208171
DO - 10.1136/jcp-2022-208171
M3 - Article
SN - 0021-9746
VL - 76
SP - 770
EP - 777
JO - Journal of Clinical Pathology
JF - Journal of Clinical Pathology
IS - 11
ER -